AbbVie Faces U.S. Probe Over 100 China Trials Including 17 in Xinjiang
ABBV•A bipartisan U.S. House committee has launched national security investigations into AbbVie's involvement in over 100 clinical trials in China since 2007, including at least 17 in Xinjiang and 16 at military-linked hospitals. The company must submit detailed information on site vetting, data protection and safety standards by July 17.
1. Investigation Launch
A bipartisan coalition led by the House Select Committee on China has sent letters to AbbVie’s CEO requiring disclosure of its China trial practices. Information on trial site selection, participant consent, data protection and safety protocols is due by July 17 under the committee’s national security mandate.
2. Scope of Clinical Trials
AbbVie has conducted over 100 clinical studies in China since 2007, with 17 trials in Xinjiang and 16 at facilities linked to the Chinese military. The inquiry examines how these sites were vetted and whether company IP or patient safety may be compromised.
3. Potential Implications
Officials warn that research at military-associated hospitals could risk technology transfer and ethical breaches, while AbbVie reviews compliance with global guidelines. Investors are monitoring potential regulatory fallout and its impact on the company’s China strategy and broader drug development pipeline.
